“Towards detecting cocaine use using smartwatches in the NIDA clinical trials network: Design, rationale, and methodology.”, Contemp Clin Trials Commun, vol. 15, p. 100392, 2019.
, “Toxicity associated with adjuvant postoperative therapy for adenocarcinoma of the rectum.”, Cancer, vol. 57, no. 6, pp. 1130-4, 1986.
, “Tracking and Monitoring Trial Progress in NIDA CTN Studies”, in NIH Workshop on Enrollment and Retention of Participants in NIH-funded Clinical Trials, Bethesda, MD, 2014.
, “Tracking of regulatory documents in a large clinical trial, The Age-Related Eye Disease Study 2”, in Society for Clinical Trials, Miami, FL, 2012.
, “Trajectory of adherence behavior in pediatric and adolescent liver transplant recipients: The medication adherence in children who had a liver transplant cohort.”, Liver Transpl, vol. 24, no. 1, pp. 80-88, 2018.
, “Transcriptional Profiling of Egg Allergy and Relationship to Disease Phenotype.”, PLoS One, vol. 11, no. 10, p. e0163831, 2016.
, “Transcriptomic and Metabolic Responses to a Live-Attenuated Vaccine.”, Vaccines (Basel), vol. 8, no. 3, 2020.
, “Transendocardial Mesenchymal Stem Cells and Mononuclear Bone Marrow Cells for Ischemic Cardiomyopathy: The TAC-HFT Randomized Trial”, JAMA, vol. 311, pp. 62-73, 2014.
, “Transition from On-Site to Remote Site Initiation Activities”, in Society of Clinical Research Associates (SOCRA), Virtual, 2021.
, “Transitioning Paper to Electronic Case Report Forms Mid-Study From One Clinical Research Organization to Another”, in The Society for Clinical Trials 33rd Annual Meeting, Miami, FL, 2012.
, “Transitioning to the Remote Collection of Urine Specimens for Urine Drug Screening During COVID-19.”, in Society for Clinical Trials (SCT) Annual Conference, Virtual, 2021.
, “Transitioning to the Remote Collection of Urine Specimens for Urine Drug Screening During COVID-19”. 2021.
, , “Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer.”, N Engl J Med, vol. 386, no. 24, pp. 2273-2282, 2022.
, “Treatment of Geographic Atrophy by the Topical Administration of OT-551: Results of a Phase II Clinical Trial”, Invest Ophthlmol Vis Sci, vol. 51, pp. 613-619, 2010.
, “Treatment of geographic atrophy by the topical administration of OT-551: results of a phase II clinical trial.”, Invest Ophthalmol Vis Sci, vol. 51, no. 12, pp. 6131-9, 2010.
, “Treatment of Geographic Atrophy with Intravitreal Sirolimus: The Age-Related Eye Disease Study 2 Ancillary Study.”, Ophthalmol Retina, vol. 2, no. 5, pp. 441-450, 2018.
, “Treatment of geographic atrophy with subconjunctival sirolimus: results of a phase I/II clinical trial.”, Invest Ophthalmol Vis Sci, vol. 54, no. 4, pp. 2941-50, 2013.
, “Treatment of Geographic Atrophy with Subconjunctival Sirolimus: Results of a Phase I/II Clinical Trial”, Invest Ophthalmol Vis Sci, vol. 54, pp. 2941-2950, 2013.
, “Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients.”, J Clin Oncol, vol. 16, no. 9, pp. 3007-15, 1998.
, , “Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: A phase I/II clinical trial”, Proceedings of the National Academy of Science USA, vol. 96, pp. 7462-66, 1999.
, “Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial.”, Proc Natl Acad Sci U S A, vol. 96, no. 13, pp. 7462-6, 1999.
, “Treatment of older patients with high-risk myelodysplastic syndromes (MDS): the emerging role of allogeneic hematopoietic stem cell transplantation (Allo HSCT).”, Curr Hematol Malig Rep, vol. 9, no. 1, pp. 57-65, 2014.
, “Treatment of Older Patients with High-Risk Myelodysplastic Syndromes (MDS): the Emerging Role of Allogeneic Hematopoietic Stem Cell Transplantation (Allo HSCT)”, Curr Hematol Malig Rep, vol. 9, pp. 57-65, 2014.
,